[EN] BACTERIAL EFFLUX PUMP INHIBITORS<br/>[FR] INHIBITEURS DE POMPE D'EFFLUX BACTÉRIEN
申请人:LAVOIE EDMOND J
公开号:WO2018165612A1
公开(公告)日:2018-09-13
Disclosed herein are compounds of formula I and salts thereof. Also disclosed are compositions comprising compounds of formula I and methods using compounds of formula I.
本文披露了公式I的化合物及其盐。还披露了包含公式I化合物的组合物和使用公式I化合物的方法。
[EN] INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS<br/>[FR] DÉRIVÉS D'INDOLE UTILISÉS EN TANT QU'INHIBITEURS DE POMPE D'EFFLUX
申请人:LAVOIE EDMOND J
公开号:WO2018165611A1
公开(公告)日:2018-09-13
Disclosed herein are compounds of formula (I): and salts thereof. Also disclosed are compositions comprising compounds of formula I and compounds of formula I for use in treating or preventing bacterial infections.
The Influence of Linker Geometry in Bis(3-hydroxy-N-methyl-pyridin-2-one) Ligands on Solution Phase Uranyl Affinity
作者:Géza Szigethy、Kenneth N. Raymond
DOI:10.1002/chem.201002372
日期:2011.2.7
unsubstituted reference ligands. Uranylaffinity was found to follow no discernable trends with incremental geometric modification. The butyl‐linked 4 li‐Me‐3,2‐HOPO ligand exhibited the highest uranylaffinity, consistent with prior in vivo decorporation results. Of the rigidly‐linkedligands, the o‐phenylene linker imparted the best uranylaffinity to the bis‐Me‐3,2‐HOPO ligand platform.
The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the present invention provides compounds represented by the following formula (1), and pharmaceutically acceptable salts thereof:
wherein X, R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, L
1
, L
2
, and L
3
are as defined in the specification.
The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the present invention provides compounds represented by the following formula (1), and pharmaceutically acceptable salts thereof:
wherein X, R1, R2, R3, R4, R5, R6, R7, L1, L2, and L3 are as defined in the specification.